Telomir Pharmaceuticals, Inc. (TELO)
NASDAQ: TELO · Real-Time Price · USD
1.300
+0.160 (14.04%)
Mar 31, 2026, 4:00 PM EDT - Market closed
Company Description
Telomir Pharmaceuticals, Inc., a preclinical-stage biotechnology company, focuses on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases.
It is developing Telomir-1, an oral small molecule metal ion regulator designed to protect against age-related conditions, including Wilson’s disease, Type 2 diabetes, age-related macular degeneration (AMD), oncology, and epigenetic regulation, as well as Alzheimer’s disease and Progeria.
The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022.
Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Miami, Florida.
Telomir Pharmaceuticals, Inc.
| Country | United States |
| Founded | 2021 |
| IPO Date | Feb 9, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 9 |
| CEO | Erez Aminov |
Contact Details
Address: 100 SE 2nd Street, Suite 2000 #1009 Miami, Florida 33131 United States | |
| Phone | 786 396 6723 |
| Website | telomirpharma.com |
Stock Details
| Ticker Symbol | TELO |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $7.00 |
| CIK Code | 1971532 |
| CUSIP Number | 87975F104 |
| ISIN Number | US87975F1049 |
| Employer ID | 87-2606031 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Erez Aminov | Chairman of the Board and Chief Executive Officer |
| Alan Weichselbaum C.P.A., M.B.A. | Chief Financial Officer |
| Dr. Itzchak Angel Ph.D. | Chief Scientific Advisor |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 31, 2026 | 8-K | Current Report |
| Mar 31, 2026 | 8-K | Current Report |
| Mar 27, 2026 | 8-K | Current Report |
| Mar 17, 2026 | 10-K | Annual Report |
| Feb 19, 2026 | DEFM14A | Filing |
| Feb 19, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Feb 17, 2026 | 8-K | Current Report |
| Feb 12, 2026 | SCHEDULE 13G/A | Filing |
| Feb 5, 2026 | 8-K | Current Report |
| Feb 5, 2026 | PRER14A | Filing |